ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 129 for:    Recruiting, Not yet recruiting, Available Studies | "Osteosarcoma"
Previous Study | Return to List | Next Study

The Osteosarcoma Biobank in Peking University People's Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03362086
Recruitment Status : Not yet recruiting
First Posted : December 5, 2017
Last Update Posted : December 5, 2017
Sponsor:
Information provided by (Responsible Party):
Ren tingting, Peking University People's Hospital

Brief Summary:
Osteosarcoma is very rare bone tumor. The investigator set up the biobank to ensure the patients has the chance to participate in future research

Condition or disease
Osteosarcoma

Detailed Description:

Samples of blood and other stored material such as slides,frozen tissues and so on .

Questionnaire information, including health history, growth and development, physical activity and family medical history information.


Study Type : Observational
Estimated Enrollment : 180 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Establishment of Osteosarcoma Biobank
Estimated Study Start Date : February 1, 2018
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : February 1, 2024

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Examine VEGFR-2 and PD-L1 gene expression osteosarcoma [ Time Frame: 3 years ]
    To examine the VEGFR2 and programmed cell death ligand 1 (PD-L1) genes expression of the patients with osteosarcoma.And Analyze their differences.


Biospecimen Retention:   Samples Without DNA
The investigator will collect pecimen and blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
the patients diagnosed with osteosarcoma without pulmonary metastasis
Criteria

Inclusion Criteria:

Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma

Exclusion Criteria:

non-asian pulmonary metastasis


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362086


Contacts
Contact: Kuisheng Liu, phD +8601088324471 liukuisheng01@163.com

Sponsors and Collaborators
Peking University People's Hospital
Investigators
Principal Investigator: Tingting Ren, phD Peking University People's Hospital

Responsible Party: Ren tingting, Lab manager of Musculoskeletal Tumor Center, Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT03362086     History of Changes
Other Study ID Numbers: PKU-osteosarcoma
First Posted: December 5, 2017    Key Record Dates
Last Update Posted: December 5, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ren tingting, Peking University People's Hospital:
bone tumor osteosarcoma

Additional relevant MeSH terms:
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma